RPL17 and lung cancer: Furthermore, the accumulation of regulatory CD4+ T cells in the tumor center may impair the ability of CD8+ T cells to proliferate in response to antigens [43], although the increased proliferation of PD-1+ CD8+ T cells in peripheral blood after PD-1-targeting therapy in lung cancer patients may overcome it [44].